Looking Ahead: Medicare in 2023 and Beyond
Next year, the Medicare enrollment process will finally receive long overdue updates, modernization, and simplification through the implementation of the
The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.
Next year, the Medicare enrollment process will finally receive long overdue updates, modernization, and simplification through the implementation of the
According to a new U.S. Department of Health and Human Services (HHS) analysis, in 2022, the list prices of over
—Statement from Fred Riccardi, Medicare Rights Center President— Washington DC—The Medicare Rights Center strongly supports the Inflation Reduction Act of
As recently outlined, the Inflation Reduction Act of 2022 incorporates many of Medicare Rights’ long-standing recommendations to meaningfully improve the
Last week, Senate Democrats released updated prescription drug pricing legislation, with the goal of passing it through the reconciliation process
This is part 3 of the helpline trends report series. Read part 1, part 2, and part 4. This third
Medicare Rights recently joined over 70 organizations to launch the campaign “Push For Lower Rx Prices.” The groups are calling
Medicare drug prices keep rising faster than inflation, and 8 in 10 adults say the cost of prescription drugs is
A recently released report from the Urban Institute shows that a firm limit on out-of-pocket (OOP) Part D costs, like
A new brief from the Kaiser Family Foundation (KFF) examines the often extreme cost liability that Part B covered drugs—typically,
Next year, the Medicare enrollment process will finally receive long overdue updates, modernization, and simplification through the implementation of the
According to a new U.S. Department of Health and Human Services (HHS) analysis, in 2022, the list prices of over
—Statement from Fred Riccardi, Medicare Rights Center President— Washington DC—The Medicare Rights Center strongly supports the Inflation Reduction Act of
As recently outlined, the Inflation Reduction Act of 2022 incorporates many of Medicare Rights’ long-standing recommendations to meaningfully improve the
Last week, Senate Democrats released updated prescription drug pricing legislation, with the goal of passing it through the reconciliation process
This is part 3 of the helpline trends report series. Read part 1, part 2, and part 4. This third
Medicare Rights recently joined over 70 organizations to launch the campaign “Push For Lower Rx Prices.” The groups are calling
Medicare drug prices keep rising faster than inflation, and 8 in 10 adults say the cost of prescription drugs is
A recently released report from the Urban Institute shows that a firm limit on out-of-pocket (OOP) Part D costs, like
A new brief from the Kaiser Family Foundation (KFF) examines the often extreme cost liability that Part B covered drugs—typically,